Machina Medical

Machina Medical is a private, pre-revenue medical device company focused on addressing uncontrolled post-traumatic hemorrhage, a leading cause of preventable death in both military and civilian settings. The company's core innovation is the MFUSE technology, a next-generation hemostatic wound care solution designed for use by military personnel, first responders, and in trauma centers. Operating in the stagnant hemostatic agent market, Machina aims to challenge decades-old foundational science with a novel approach, positioning itself to capture significant share in a large and critical global market.

MFUSE, a next-generation hemostatic wound care technology designed to control severe, life-threatening bleeding through a novel material science approach, providing critical time for patient transport to definitive care.

Machina competes in the advanced hemostatic agent market against established players like Z-Medica (QuikClot), Celox, HemCon, and Baxter. These competitors have widely adopted products based on materials like kaolin and chitosan. Machina's strategy is to differentiate by claiming a foundational technological innovation rather than an incremental improvement.